Drug Profile
ABS 103
Latest Information Update: 24 Jan 2001
Price :
$50
*
At a glance
- Originator American Biogenetic Sciences [CEASED]
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 24 Jan 2001 Discontinued-Preclinical for Epilepsy in USA (Unknown route)
- 04 Feb 2000 Abbott has licensed worldwide rights to ABS 103
- 02 Feb 2000 Preclinical development for Epilepsy in USA (Unknown route)